IDH1 and central nervous system cancer: These types of experiments should ideally be conducted in patient-derived glioma cells that intrinsically harbor IDH mutations in comparison to those that are IDH wild-type, as this would be more representative of a real-world scenario and account for greater genetic variability beyond the idealized U87R132H model.